Abstract
In summary, while AIs are a welcome addition to the repertoire of endocrine interventions for the treatment of breast cancer, further studies are warranted to elucidate their long-term effects. Other tumor-related characteristics and host factors may predict not only efficacy but also AI-associated safety. Early recognition and management of adverse effects is crucial for maintaining adherence and achieving the maximum benefit from therapy. Additional follow-up is required to establish the long-term safety of the agents. Until further information becomes available, clinicians are encouraged to utilize AIs in the setting in which they have been studied and approved.
Original language | English (US) |
---|---|
Pages (from-to) | 1-4 |
Number of pages | 4 |
Journal | Expert Review of Anticancer Therapy |
Volume | 8 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2008 |
ASJC Scopus subject areas
- Oncology
- Pharmacology (medical)